Ge Long Hui·2025-08-01 02:20Group 1 - The core viewpoint of the news is the significant rise in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to increased investor interest in related companies [1][2] - Companies such as Lide Man, Lianhuan Pharmaceutical, and Rejing Bio have seen substantial stock price increases, with Lide Man reaching a 20% limit up and Lianhuan Pharmaceutical achieving a nearly 10% increase [1][2] - The treatment plan emphasizes preventive measures against Chikungunya virus, including mosquito control and personal protective measures, highlighting the ongoing public health concern and the lack of available vaccines in China [1] Group 2 - Specific stock performance data shows Lide Man with a 20.03% increase, Lianhuan Pharmaceutical with a 9.98% increase, and Rejing Bio with a 9.25% increase, indicating strong market reactions [2] - Year-to-date performance reveals that Rejing Bio has surged by 244.50%, while Lianhuan Pharmaceutical has increased by 97.68%, showcasing the potential for continued growth in the sector [2] - Other companies such as Zhongsheng Pharmaceutical and Maiwei Niuwu also experienced notable gains, further indicating a broader trend in the virus prevention sector [1][2]